Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Abstract Background Switch strategies based on rilpivirine/tenofovir/emtricitabine or on an integrase inhibitor (InSTI) plus tenofovir/emtricitabine have never been compared in randomized clinical trials. The main aim of the study was to investigate the durability of these two switch regimens in vir...

Full description

Bibliographic Details
Main Authors: Nicola Gianotti, Andrea Poli, Silvia Nozza, Laura Galli, Nadia Galizzi, Marco Ripa, Marco Merli, Alessia Carbone, Vincenzo Spagnuolo, Adriano Lazzarin, Antonella Castagna
Format: Article
Language:English
Published: BMC 2017-11-01
Series:BMC Infectious Diseases
Subjects:
Rilpivirine
Raltegravir
Elvitegravir/cobicistat
Dolutegravir
Non-nucleoside reverse transcriptase inhibitors
Integrase inhibitors
Online Access:http://link.springer.com/article/10.1186/s12879-017-2831-9

Internet

http://link.springer.com/article/10.1186/s12879-017-2831-9

Similar Items